Prevalence and management of chronic kidney disease in primary care patients in the UK

2014 ◽  
Vol 68 (9) ◽  
pp. 1110-1121 ◽  
Author(s):  
K. Jameson ◽  
S. Jick ◽  
K. W. Hagberg ◽  
B. Ambegaonkar ◽  
A. Giles ◽  
...  
2019 ◽  
Vol 184 (17) ◽  
pp. 526-526 ◽  
Author(s):  
Megan Conroy ◽  
David C Brodbelt ◽  
Dan O’Neill ◽  
Yu-Mei Chang ◽  
Jonathan Elliott

Chronic kidney disease (CKD) is a frequent diagnosis in cats attending primary care practice and the most frequent cause of death in cats aged over five years, yet there is limited published research for CKD in cats attending primary care practice. This study aimed to estimate the prevalence of CKD and investigate risk factors for diagnosis and survival of cats diagnosed with CKD in UK primary care practices. The study included cats attending VetCompassTM practices from January 1, 2012 to December 31, 2013. A nested case-control and cohort study were undertaken. From 353,448 cats attending 244 clinics, the prevalence of CKD was estimated as 1.2 per cent (95 per cent CI 1.1 per cent to 1.3 per cent). Most cats with CKD had clinical signs at diagnosis (66.6 per cent). Few cats underwent investigations or monitoring of serum creatinine (32.6 per cent), urine protein:creatinine ratio (14.9 per cent) or blood pressure measurement (25.6 per cent). A proprietary renal diet was the most frequently prescribed management (63.8 per cent). Median survival time following diagnosis was 388 days (IQR 88–1042 days). This study provides generalisable evidence from the wider cat population to aid veterinarians in improved diagnosis and management of CKD that can benefit the health and welfare of cats with CKD in the UK.


QJM ◽  
2011 ◽  
Vol 105 (2) ◽  
pp. 167-175 ◽  
Author(s):  
M. P. Hossain ◽  
D. Palmer ◽  
E. Goyder ◽  
A. M. El Nahas

2012 ◽  
Vol 13 (1) ◽  
Author(s):  
Wai Leng Chow ◽  
Veena D Joshi ◽  
Aung Soe Tin ◽  
Saskia van der Erf ◽  
Jeremy Fung Yen Lim ◽  
...  

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i155-i155
Author(s):  
Ben Caplin ◽  
Sally Hull ◽  
Faye Cleary ◽  
Kathleen Mudie ◽  
David Wheeler ◽  
...  

2012 ◽  
Vol 62 (597) ◽  
pp. e227-e232 ◽  
Author(s):  
Natasha J McIntyre ◽  
Richard Fluck ◽  
Chris McIntyre ◽  
Maarten Taal

Author(s):  
Harjeet K. Bhachu ◽  
Paul Cockwell ◽  
Anuradhaa Subramanian ◽  
Nicola J. Adderley ◽  
Krishna Gokhale ◽  
...  

2020 ◽  
Author(s):  
Ronald L Castelino ◽  
Timothy Saunder ◽  
Alex Kitsos ◽  
Greg Peterson ◽  
Matthew Jose ◽  
...  

Abstract Objective: To determine the extent of potentially inappropriate prescribing (PIP; defined as the use of a contraindicated medication or inappropriately high dose according to the kidney function) of renally-cleared medications commonly prescribed in Australian primary care, based on two measures of kidney function. A secondary aim was to assess agreement between the two measures.Design: Retrospective analysis of routinely collected de-identified Australian general practice patient data (NPS MedicineWise MedicineInsight from January 1, 2013, to June 1, 2016; collected from 329 general practices). Setting & Participants: All adults (aged ≥18 years) with chronic kidney disease (CKD) presenting to general practices across Australia.Results: A total of 48,731 patients met the Kidney Health Australia (KHA) definition for CKD and had prescriptions recorded within 90 days of measuring serum creatinine (SCr)/estimated glomerular filtration rate (eGFR). Overall, 28,729 patients were prescribed one or more of the 49 medications of interest. Approximately 35% (n=9,926) of these patients had at least one PIP based on either the Cockcroft-Gault (CG) equation or eGFR (CKD-EPI; CKD-Epidemiology Collaboration Equation). There was good agreement between CG and eGFR while determining the appropriateness of medications, with approximately 97% of the medications classified as appropriate by eGFR also being considered appropriate by the CG equation.Conclusion: This study highlights that PIP commonly occurs in primary care patients with CKD and the need for further research to understand why and how this can be minimised. The findings also show that the eGFR provides clinicians a potential alternative to the CG formula when estimating kidney function to guide drug appropriateness and dosing.


2017 ◽  
Vol 67 (663) ◽  
pp. e732-e735
Author(s):  
Daniel S Lasserson ◽  
Brian Shine ◽  
Christopher A O’Callaghan ◽  
Tim James

BackgroundCreatinine-based estimated glomerular filtration rate (eGFR) determines chronic kidney disease (CKD) stage, but underestimates renal function. The 2014 updated guidance from the National Institute for Health and Care Excellence (NICE) recommends that GPs reduce overdiagnosis of CKD stage 3a (eGFR 45–60 ml/min/1.73 m2) by using the renal biomarker cystatin C.AimTo determine the population requirement for cystatin C testing, compared with current national availability of the assay.Design and settingRetrospective study of primary care laboratory requests in Oxfordshire, England.MethodThe first creatinine results from tests ordered in primary care over a 6-year period (2008–2014) in a population of 600 000 in Oxfordshire were analysed and the number of patients with CKD stage 3a without proteinuria (who, in accordance with NICE guidance, required cystatin C) was determined. A conservative estimate of the national need was provided by scaling the population of Oxfordshire to the national population (CKD prevalence in the county is below the national average). Cystatin C assay availability was determined using national databases of laboratory assay provision.ResultsFrom a population of 600 000, there were 22 240 individuals with stable stage 3a CKD and no proteinuria. As the population of Oxfordshire equates to 1% of the UK population, there is an initial requirement for at least 2 million people to have their CKD status determined with cystatin C testing. Eight laboratories (2.1% of UK laboratories) reported cystatin C assay provision.ConclusionThere is a substantial gap between cystatin C assay requirements in primary care and national assay provision. This is a major barrier to implementing NICE guidance.


Sign in / Sign up

Export Citation Format

Share Document